Skip to main content

Table 5 summary of studies with chemoradiotherapy plus bevacizumab

From: Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer

Study Phase N. of patients Staging Radiotherapy Gy/fractions/weeks Bevacizumab Concomitant chemotherapy pCR N.% Downstaging N.% R0%
Czito et al. [14] I 11 II-IV 50.4/28/5.5 15 mg/Kg 1st dose Capecitabine: 500–825 mg/m2/bid 5 days/week 2/11 18.2% Overall: 81.8% 81.8%
10 mg/Kg days 8, 22 Oxaliplatin 50–75 mg/m2/1, 8, 15, 22, 29
Willett et a [10] II 32 T3-T4 50.4/28/5.5 5-10 mg/Kg days 1, 8, 15, 22 Fluorouracile: 225 mg/m2/24 hours/4 cycles 5/32 16% T stage: 50% N stage: 56.5% 93.7%
Crane et al. [16] II 25 T3N0/T3N1 50.4/28/5.5 5 mg/Kg 3 doses Capecitabine: 900 mg/m2/bid 5 days/week 8/25 32% T stage: 64% N stage: 15% 100%
Nogué et al. [18] II 47 T3N0-T4N2 50.4/25/5.5 7 mg/Kg induction 4 cycles Capecitabine: 825 mg/m2/bid 5 days/week 16/45 36% - 97.9%
5 mg/Kg days 1, 15, 29
Koukourakis et al. [17] II 19 T3 and/or N+ Hypofractionated accelerated 5 mg/Kg 2 doses Capecitabine: 600 mg/m2/bid 5 days/week 7/19 36.8% - -
[19] II 61 T2N1-T4N2 50.4/28/5.5 5 mg/Kg days −14, 1, 15, 29 Capecitabine: 825 mg/m2/bid 5 days/week 8/60 13.3% T stage: 64% N stage: 15% Overall: 73.8% 95%
Dipetrillo et al. [20] II 26 T2N0-T4Nx 50.4/25/5.5 5 mg/Kg days induction and then days 1, 15, 29 Fluorouracile: 200 mg/m2/24 hours 5/25 20% - -
Oxaliplatin 50 mg/m2/1, 8, 15, 22, 29, 36
Landry et al. [24] II 57 T3-T4 50.4/28/5.5 5 mg/Kg days 1, 15, 29 Capecitabine: 825 mg/m2/bid 5 days/week 9/57 17% Overall: 59% -
Oxaliplatin 50 mg/m2/1, 8, 15, 22, 29
Gasparini et al. [21] II 43 T2N1-T4N2 50.4/28/5.5 5 mg/Kg days −14, 1, 15, 29 Capecitabine: 825 mg/m2/bid 5 days/week 6/43 14% T Stage: 34.9% N stage: 41.86% -
Spigel et al. [23] II 35 (cohort A) II/III 50.4/28/5.5 5 mg/Kg days 1, 15 Fluorouracile: 225 mg/m2/24 hours days 1 to 42 10/35 29% - -
Resch et al. [22] II 8 cT3 45/-/5 5 mg/Kg days 1, 15, 29 Capecitabine: 825 mg/m2/bid 5 days/week 4 weeks 2/8 25% Overall: 37.5% -
Kennecke et al. [15] II 42 T2-T4 N2 50.4/28/5.5 5 mg/Kg days −14, 1, 15, 29 Capecitabine: 825 mg/m2/bid days 1–14, 22-35 7/42 18.4% - 92%
Oxaliplatin 50 mg/m2/1, 8, 22, 29